Inhibition of differentiation of cytotoxic T-cells by P-selectin ligand (PSGL) antagonists
AssigneeGenetics Institute, Inc.
InventorsNarasimhaswamy Manjunath, Ulrich Hans von Andrian
Life of this patent
Estimating the term…
Abstract
Methods are disclosed for inhibiting the differentiation of an activated T-cell into a cytotoxic lymphocyte in a mammalian subject, comprising administering to a subject a therapeutically effective amount of a PSGL antagonist.
Claims25
A method of inhibiting the differentiation of an activated T-cell into a cytotoxic lymphocyte in a mammalian subject, said method comprising administering to said subject a therapeutically effective amount of a PSGL antagonist.
A method of treating or ameliorating an autoimmune condition, said method comprising administering to said subject a therapeutically effective amount of a PSGL antagonist.
A method of treating or ameliorating a allergic reaction, said method comprising administering to said subject a therapeutically effective amount of a PSGL antagonist.
A method of treating or ameliorating asthma, said method comprising administering to said subject a therapeutically effective amount of a PSGL antagonist.
Dependencies are inferred from the claim text.